Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 328

1.

Guidelines for the management of familial hypercholesterolemia.

Harada-Shiba M, Arai H, Oikawa S, Ohta T, Okada T, Okamura T, Nohara A, Bujo H, Yokote K, Wakatsuki A, Ishibashi S, Yamashita S.

J Atheroscler Thromb. 2012;19(12):1043-60. Epub 2012 Oct 25.

2.

Multicenter study to determine the diagnosis criteria of heterozygous familial hypercholesterolemia in Japan.

Harada-Shiba M, Arai H, Okamura T, Yokote K, Oikawa S, Nohara A, Okada T, Ohta T, Bujo H, Watanabe M, Wakatsuki A, Yamashita S.

J Atheroscler Thromb. 2012;19(11):1019-26. Epub 2012 Oct 25.

3.

The molecular genetic basis and diagnosis of familial hypercholesterolemia in Denmark.

Jensen HK.

Dan Med Bull. 2002 Nov;49(4):318-45. Review.

PMID:
12553167
4.

Clinical features of familial hypercholesterolemia in Japan in a database from 1996-1998 by the research committee of the ministry of health, labour and welfare of Japan.

Bujo H, Takahashi K, Saito Y, Maruyama T, Yamashita S, Matsuzawa Y, Ishibashi S, Shionoiri F, Yamada N, Kita T; Research Committeon Primary Hyperlipidemia of the Ministry of Health, Labour, and Welfare of Japan.

J Atheroscler Thromb. 2004;11(3):146-51.

5.

Familial Hypercholesterolemia.

Youngblom E, Pariani M, Knowles JW.

In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2018.
2014 Jan 2 [updated 2016 Dec 8].

6.

Coronary artery disease in heterozygous familial hypercholesterolemia patients with the same LDL receptor gene mutation.

Ferrières J, Lambert J, Lussier-Cacan S, Davignon J.

Circulation. 1995 Aug 1;92(3):290-5.

7.

A Chinese homozygote of familial hypercholesterolemia: identification of a novel C263R mutation in the LDL receptor gene.

Wang D, Wu B, Li Y, Heng W, Zhong H, Mu Y, Wang J.

J Hum Genet. 2001;46(3):152-4.

PMID:
11310584
8.

A xanthomatosis-susceptibility gene may exist in a Syrian family with familial hypercholesterolemia.

Vergopoulos A, Bajari T, Jouma M, Knoblauch H, Aydin A, Bähring S, Mueller-Myhsok B, Dresel A, Joubran R, Luft FC, Schuster H.

Eur J Hum Genet. 1997 Sep-Oct;5(5):315-23.

PMID:
9412789
9.

Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society.

Nordestgaard BG, Chapman MJ, Humphries SE, Ginsberg HN, Masana L, Descamps OS, Wiklund O, Hegele RA, Raal FJ, Defesche JC, Wiegman A, Santos RD, Watts GF, Parhofer KG, Hovingh GK, Kovanen PT, Boileau C, Averna M, Borén J, Bruckert E, Catapano AL, Kuivenhoven JA, Pajukanta P, Ray K, Stalenhoef AF, Stroes E, Taskinen MR, Tybjærg-Hansen A; European Atherosclerosis Society Consensus Panel.

Eur Heart J. 2013 Dec;34(45):3478-90a. doi: 10.1093/eurheartj/eht273. Epub 2013 Aug 15.

10.

Long term effect of LDL apheresis in Japan. LDL Apheresis Study Group.

Naito C, Yamamoto A, Saito Y, Muto E, Nishide T, Shinomiya M, Mukai M, Tomono S, Sato T, Yasuda K, et al.

Biomater Artif Cells Immobilization Biotechnol. 1991;19(1):19-26.

PMID:
1751669
11.

Apheresis technology for prevention and regression of atherosclerosis.

Yamamoto A, Harada-Shiba M, Kawaguchi A, Tsushima M.

Ther Apher. 2001 Aug;5(4):221-5. Review.

PMID:
11724504
12.

Defining patients at extremely high risk for coronary artery disease in heterozygous familial hypercholesterolemia.

Sugisawa T, Okamura T, Makino H, Watanabe M, Kishimoto I, Miyamoto Y, Iwamoto N, Yamamoto A, Yokoyama S, Harada-Shiba M.

J Atheroscler Thromb. 2012;19(4):369-75. Epub 2012 Feb 15.

13.

Familial defective apolipoprotein B versus familial hypercholesterolemia: an assessment of risk.

Fouchier SW, Defesche JC, Kastelein JJ, Sijbrands EJ.

Semin Vasc Med. 2004 Aug;4(3):259-64.

PMID:
15630635
14.

Low-density lipoprotein apheresis for prevention and regression of atherosclerosis: clinical results.

Bambauer R, Olbricht CJ, Schoeppe E.

Ther Apher. 1997 Aug;1(3):242-8.

PMID:
10225746
15.

DNA testing for familial hypercholesterolemia: improving disease recognition and patient care.

Vergopoulos A, Knoblauch H, Schuster H.

Am J Pharmacogenomics. 2002;2(4):253-62. Review.

PMID:
12421096
16.

Diagnostic Yield and Clinical Utility of Sequencing Familial Hypercholesterolemia Genes in Patients With Severe Hypercholesterolemia.

Khera AV, Won HH, Peloso GM, Lawson KS, Bartz TM, Deng X, van Leeuwen EM, Natarajan P, Emdin CA, Bick AG, Morrison AC, Brody JA, Gupta N, Nomura A, Kessler T, Duga S, Bis JC, van Duijn CM, Cupples LA, Psaty B, Rader DJ, Danesh J, Schunkert H, McPherson R, Farrall M, Watkins H, Lander E, Wilson JG, Correa A, Boerwinkle E, Merlini PA, Ardissino D, Saleheen D, Gabriel S, Kathiresan S.

J Am Coll Cardiol. 2016 Jun 7;67(22):2578-89. doi: 10.1016/j.jacc.2016.03.520. Epub 2016 Apr 3.

17.

Elevated lipoprotein(a), hypertension and renal insufficiency as predictors of coronary artery disease in patients with genetically confirmed heterozygous familial hypercholesterolemia.

Chan DC, Pang J, Hooper AJ, Burnett JR, Bell DA, Bates TR, van Bockxmeer FM, Watts GF.

Int J Cardiol. 2015 Dec 15;201:633-8. doi: 10.1016/j.ijcard.2015.08.146. Epub 2015 Aug 21.

PMID:
26340131
18.

Familial hypercholesterolemia--improving treatment and meeting guidelines.

Hopkins PN.

Int J Cardiol. 2003 May;89(1):13-23. Review.

PMID:
12727001
19.

Evaluation of coronary risk factors in patients with heterozygous familial hypercholesterolemia.

Hopkins PN, Stephenson S, Wu LL, Riley WA, Xin Y, Hunt SC.

Am J Cardiol. 2001 Mar 1;87(5):547-53.

PMID:
11230837

Supplemental Content

Support Center